Structure of L1198F Mutant Human Anaplastic Lymphoma Kinase in Complex with PF-06463922 ((10R)-7-amino-12-fluoro-2,10,16-trimethyl- 15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11) benzoxadiazacyclotetradecine-3-carbonitrile).

Structure of L1198F Mutant Human Anaplastic Lymphoma Kinase in Complex with PF-06463922 ((10R)-7-amino-12-fluoro-2,10,16-trimethyl- 15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11) benzoxadiazacyclotetradecine-3-carbonitrile). Descriptor: (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile, ALK TYROSINE KINASE RECEPTOR Authors: McTigue, M, Deng, Y.-L, Liu, W, Brooun, A, Stewart, A. Deposit date: 2015-07-23 Release date: 2016-06-08 Last modified: 2024-01-10 Method: X-RAY DIFFRACTION (1.93 Å) Cite: Resensitization to Crizotinib by the Lorlatinib Alk Resistance Mutation L1198F. N.Engl.J.Med., 374, 2016

与PF-06463922（(10R)-7-氨基-12-氟-2,10,16-三甲基-15-氧代-10,15,16,17-四氢-2H-8,4-(亚甲基)吡唑并[4,3-h][2,5,11]苯并氧二氮杂环十四烷-3-腈）结合的L1198F突变型人源间变性淋巴瘤激酶（Anaplastic Lymphoma Kinase, ALK）的结构。描述项：(10R)-7-氨基-12-氟-2,10,16-三甲基-15-氧代-10,15,16,17-四氢-2H-8,4-(亚甲基)吡唑并[4,3-h][2,5,11]苯并氧二氮杂环十四烷-3-腈、间变性淋巴瘤激酶酪氨酸激酶受体；作者：McTigue M、Deng Y.-L、Liu W、Brooun A、Stewart A；提交日期：2015-07-23；发布日期：2016-06-08；最后修改日期：2024-01-10；检测方法：X射线衍射（分辨率1.93埃）；引用文献：《洛拉替尼耐药突变L1198F可恢复对克唑替尼的敏感性》，《新英格兰医学杂志》，第374卷，2016年